Ellansé and Sculptra are the two collagen stimulators most often weighed against each other once Radiesse has been ruled out, and they are not regulated the same way. Sculptra is poly-L-lactic acid with US approval since 2004; Ellansé is polycaprolactone, sold in Europe and elsewhere under a CE mark and not approved in the US. This page compares them on what can be checked as of 3 November 2026. It takes no side and does not say which suits any face.
Each has its own page with the full record: Ellansé carries the polycaprolactone trial table, and Sculptra the approval history and the US trials. The wider class, including Radiesse and the PDLLA fillers, is sorted on biostimulators; the calcium hydroxylapatite pairing is on Sculptra vs Radiesse.
Two polymers, two ways of arriving
| Ellansé | Sculptra | |
|---|---|---|
| Material | polycaprolactone (PCL) microspheres, 25–50 µm, in a carboxymethylcellulose gel | poly-L-lactic acid (PLLA), a biodegradable polymer supplied as a freeze-dried powder |
| Preparation | supplied ready to inject | mixed with sterile water before use |
| Volume on the day | yes — the gel fills at first and is absorbed over weeks | little that lasts; the water is absorbed within days |
| What is credited with the later effect | tissue response around the microspheres | tissue response around the PLLA particles |
| Versions | Ellansé-S and Ellansé-M, given different durations (at least 18 and 24 months) by consultants to the distributor | one product |
| Regulatory status | CE mark (Class III device), 2009; no US approval or clearance | FDA premarket approval P030050, 2004 |
| Can it be dissolved? | no enzyme dissolves it; a 2025 case series reported collagenase on nodules | no |
Both polymers were used in absorbable surgical devices — sutures, stents, scaffolds — long before they were injected into faces, which is why a literature search on the pair returns mostly engineering papers. The point of comparison a reader usually wants — how long each lasts — is where the record is thinnest, because the two products' duration figures come from different study designs and different sponsors.
Where each can be used legally
Sculptra is approved in the US for three facial uses: facial fat loss in people with HIV (3 August 2004), nasolabial folds and other facial wrinkles (28 July 2009) and fine lines and wrinkles of the cheek (25 April 2023). Its labeling names neither the under-eye area nor the temples, and our Sculptra under the eyes page sets out what it says about the eye.
Ellansé has no US approval. On 3 November 2026 the FDA premarket approval, 510(k) and device-identification databases held no record under the name or for a polycaprolactone dermal filler. It is sold in Europe, the UK, parts of Asia and Latin America under its CE mark, and a US premarket trial is under way (below). A reader in the US who is offered "Ellansé" is being offered a product with no FDA approval.
The one study that compared them in people
A PubMed search on 3 November 2026 for polycaprolactone or Ellansé together with poly-L-lactic acid, Sculptra or PLLA returned 193 records. Most are sutures, stents, scaffolds and thread lifts, where the two polymers are often blended. Read title by title, the facial-filler records are reviews, laboratory comparisons and case reports, plus one clinical comparison:
| Study | Design | Groups | Result |
|---|---|---|---|
| Hu and Wang, J Cosmet Dermatol 2025 (PMID 40874404) | retrospective chart review, one outpatient plastic-surgery clinic in Quzhou, China, treatments January–December 2023 | 65 PCL, 71 PLLA, nasolabial folds, aged 30–60 | wrinkle-severity score (lower is better) 3.08 vs 3.27 at 3 months, 2.23 vs 2.49 at 6, 1.92 vs 2.17 at 12; higher satisfaction with PCL at 6 and 12 months; no significant difference in injection-site reactions or adverse events |
The direction favours polycaprolactone, by about a quarter of a point on a five-point scale at each visit. Four limits bind it. Patients were not randomized — whoever chose PCL may have differed from whoever chose PLLA. Neither product is named, so it is not known that the PCL was Ellansé or that the PLLA was Sculptra. It is a single clinic. And the abstract does not say how the scores were rated or whether the rater knew which filler had been used. The authors declare no conflicts.
Two other records are sometimes cited as comparisons and are not. A 2026 pilot bench study photographed nine biostimulator products, PCL and PLLA among them, under the microscope and in saline for 72 hours, and states that it "does not establish reproducibility, chemical stability, or clinical performance" (Gruszczyński et al., Biomedicines 2026, PMID 42939961; one author consults for a PDLLA maker). A 2025 meta-analysis pooled 25 observational studies of calcium hydroxylapatite, PLLA and PCL together — pooled satisfaction 91%, nodules 5%, bruising 27% — without separating the materials (Smith et al., Aesthet Surg J 2025, PMID 40674466).
The trial that will report next
ClinicalTrials.gov lists no randomized trial of Ellansé against Sculptra. The US Ellansé-S trial, NCT06984835, is a double-blind, split-face study of 126 people's nasolabial folds sponsored by AQTIS Medical B.V.; its comparator is a calcium hydroxylapatite filler, its primary outcome is the change in wrinkle-severity score at 6 months, and on 3 November 2026 it was active, not recruiting, with primary completion estimated for August 2026 and no results posted. When it reports, it will say how Ellansé-S compares with calcium hydroxylapatite — not with Sculptra.
Sculptra's own US trials compared it with human collagen (the 2009 fold approval) and with no treatment (the 2023 cheek approval). So each product has been tested against something, and neither against the other.
What FDA's device-report database holds
On 3 November 2026 FDA's MAUDE database, read through openFDA (data updated 20 October 2026), held 2,038 reports naming Sculptra — 1,081 coded as injury — and 1 naming Ellansé, an eye-pain event in a trial participant in 2025, recorded as resolved. The difference is market, not material: Sculptra has been sold in the US for twenty years and Ellansé not at all, and MAUDE collects US reports. The published harm record for Ellansé sits in case reports instead — foreign-body granulomas, a 2021 sarcoidosis report and a 2026 expert consensus on managing vascular occlusion — collected on our Ellansé page. For Sculptra's nodules and their history, see Sculptra side effects.
What is and is not established
- Sculptra is FDA-approved for three facial uses; Ellansé is CE-marked and has no US approval.
- One retrospective, single-clinic study from China found slightly better fold scores with polycaprolactone than poly-L-lactic acid over 12 months, with similar side effects; it named neither brand.
- No randomized trial compares Ellansé with Sculptra, and none is registered.
- Duration claims for the two come from different studies and different sponsors and cannot be set side by side.
- Neither can be dissolved with an enzyme in the way hyaluronic acid can.
Which material suits a particular face, and whether a product without US approval is an option at all, is a question for a licensed clinician.
Sources
Opened 3 November 2026: PubMed search (polycaprolactone[tiab] OR ellanse[tiab] OR ellansé[tiab]) AND ("poly-L-lactic"[tiab] OR sculptra[tiab] OR PLLA[tiab]) (193 records, facial-filler titles read) and ellanse[tiab] OR ellansé[tiab] (21); abstracts of Hu K, Wang S, J Cosmet Dermatol 2025, PMID 40874404 (PMC12392244); Gruszczyński W et al., Biomedicines 2026, PMID 42939961; Smith L et al., Aesthet Surg J 2025, PMID 40674466. ClinicalTrials.gov API v2: NCT06984835 (last update 21 July 2026), NCT06972940, and the search "Ellanse OR polycaprolactone filler" (7 records). FDA MAUDE via openFDA device/event, device.brand_name sculptra (2,038) and ellanse (1). Sculptra approval dates and Ellansé composition and CE date as recorded, with their sources, on our Sculptra and Ellansé pages. Corrections go to the contact page.